Immunotherapy-related pneumonitis and bacterial pneumonia after the successful treatment of metastatic malignant melanoma with pembrolizumab: A case report

INTRODUCTION: Pembrolizumab, a monoclonal antibody targeting programmed cell death-1 (PD-1), is approved as a therapy for unresectable or metastatic melanoma. Immunotherapy-associated pneumonitis is an uncommon event. PATIENT CONCERNS: A 73-year-old man was admitted to our hospital with a history of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Qin, Yang, Lei, Gu, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793440/
https://www.ncbi.nlm.nih.gov/pubmed/33429766
http://dx.doi.org/10.1097/MD.0000000000024018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793440/
https://www.ncbi.nlm.nih.gov/pubmed/33429766
http://dx.doi.org/10.1097/MD.0000000000024018

Ejemplares similares